Does USTEKINUMAB Cause Therapy cessation? 381 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 381 reports of Therapy cessation have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.5% of all adverse event reports for USTEKINUMAB.
381
Reports of Therapy cessation with USTEKINUMAB
0.5%
of all USTEKINUMAB reports
1
Deaths
51
Hospitalizations
How Dangerous Is Therapy cessation From USTEKINUMAB?
Of the 381 reports, 1 (0.3%) resulted in death, 51 (13.4%) required hospitalization, and 1 (0.3%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 381 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which USTEKINUMAB Alternatives Have Lower Therapy cessation Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE